109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
一种用于三阴性乳腺癌化疗/化学动力学治疗的 pH/H₂O₂ 双响应钴锰基纳米递送系统
Authors Mei G, Lin F, Huang L, Lin M, Lin X, Huang L
Received 18 July 2025
Accepted for publication 23 October 2025
Published 5 November 2025 Volume 2025:20 Pages 13359—13379
DOI https://doi.org/10.2147/IJN.S546671
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Krishna Nune
Guanghui Mei,1 Fei Lin,1,2 Liying Huang,1 Min Lin,3 Xinhua Lin,1 Lingyi Huang1
1School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China; 2College of Chemistry, Fuzhou University, Fuzhou, 350108, People’s Republic of China; 3School of Innovation, Entrepreneurship, and Creation of Minjiang University, Fuzhou, Fujian, 350108, People’s Republic of China
Correspondence: Lingyi Huang, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China, Email lingyi.huang@fjmu.edu.cn Xinhua Lin, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China, Email 13906909638@163.com
Purpose: This study developed a dual-responsive nano-delivery system to overcome elevated glutathione (GSH) and acidic pH in the tumor microenvironment (TME), enhancing chemodynamic therapy (CDT) and chemotherapy against triple-negative breast cancer (TNBC).
Methods: A pH/H2O2-responsive nanoplatform named as ZIF-67/MnO2/DOX/BSA/SDS (ZMDBS), was developed by integrating zeolitic imidazolate framework-67 (ZIF-67) with manganese dioxide (MnO2), loading doxorubicin (DOX), then introducing bovine serum albumin (BSA) and sodium dodecyl sulfate (SDS). Under TME conditions, it released Co²⁺ and Mn²⁺ ions to promote Fenton-like reactions and reactive oxygen species (ROS) generation. Physicochemical properties, GSH/H2O2 responsiveness, ROS production, and pH-triggered DOX release were also evaluated. In vitro (cellular uptake, ROS quantification, apoptosis, and migration tests) and in vivo experiments were conducted, alongside transcriptomic profiling.
Results: Characterization results (particle size, zeta potential, FTIR, TEM, XRD, and XPS) confirmed ZMDBS as a novel cobalt/manganese-based nanocomposite, with the encapsulation rate of 95%. It efficiently depleted GSH, enhanced ROS production, and controlled DOX release under TME conditions. In vitro experiments, ZMDBS showed minimal toxicity to LO2 hepatocytes, whereas induced a two-fold ROS increase, 70.7% apoptosis in 4T1 cells (vs 40.9% for DOX), and a lower IC50 (0.35 μg/mL vs 5.00 μg/mL for DOX). In vivo, ZMDBS reduced tumor volume by 60.7% in mice without systemic toxicity (vs 31.1% for DOX). Transcriptomics revealed that ZMDBS-triggered ROS overproduction activated the p53, MAPK, and TNF pathways, culminating in caspase-mediated apoptosis.
Conclusion: ZMDBS, a pH/H2O2 dual-responsive cobalt/manganese-based nanoplatform, has remodeled the TME for synergistic CDT and chemotherapy. With high catalytic efficiency and favorable biocompatibility, it offers a promising strategy for safe and effective TNBC treatment.
Keywords: chemodynamic therapy, triple-negative breast cancer, tumor microenvironment, cobalt/manganese-based nano-delivery system, ZIF-67/MnO2/DOX/BSA/SDS
1School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China; 2College of Chemistry, Fuzhou University, Fuzhou, 350108, People’s Republic of China; 3School of Innovation, Entrepreneurship, and Creation of Minjiang University, Fuzhou, Fujian, 350108, People’s Republic of China
Correspondence: Lingyi Huang, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China, Email lingyi.huang@fjmu.edu.cn Xinhua Lin, School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China, Email 13906909638@163.com
Purpose: This study developed a dual-responsive nano-delivery system to overcome elevated glutathione (GSH) and acidic pH in the tumor microenvironment (TME), enhancing chemodynamic therapy (CDT) and chemotherapy against triple-negative breast cancer (TNBC).
Methods: A pH/H2O2-responsive nanoplatform named as ZIF-67/MnO2/DOX/BSA/SDS (ZMDBS), was developed by integrating zeolitic imidazolate framework-67 (ZIF-67) with manganese dioxide (MnO2), loading doxorubicin (DOX), then introducing bovine serum albumin (BSA) and sodium dodecyl sulfate (SDS). Under TME conditions, it released Co²⁺ and Mn²⁺ ions to promote Fenton-like reactions and reactive oxygen species (ROS) generation. Physicochemical properties, GSH/H2O2 responsiveness, ROS production, and pH-triggered DOX release were also evaluated. In vitro (cellular uptake, ROS quantification, apoptosis, and migration tests) and in vivo experiments were conducted, alongside transcriptomic profiling.
Results: Characterization results (particle size, zeta potential, FTIR, TEM, XRD, and XPS) confirmed ZMDBS as a novel cobalt/manganese-based nanocomposite, with the encapsulation rate of 95%. It efficiently depleted GSH, enhanced ROS production, and controlled DOX release under TME conditions. In vitro experiments, ZMDBS showed minimal toxicity to LO2 hepatocytes, whereas induced a two-fold ROS increase, 70.7% apoptosis in 4T1 cells (vs 40.9% for DOX), and a lower IC50 (0.35 μg/mL vs 5.00 μg/mL for DOX). In vivo, ZMDBS reduced tumor volume by 60.7% in mice without systemic toxicity (vs 31.1% for DOX). Transcriptomics revealed that ZMDBS-triggered ROS overproduction activated the p53, MAPK, and TNF pathways, culminating in caspase-mediated apoptosis.
Conclusion: ZMDBS, a pH/H2O2 dual-responsive cobalt/manganese-based nanoplatform, has remodeled the TME for synergistic CDT and chemotherapy. With high catalytic efficiency and favorable biocompatibility, it offers a promising strategy for safe and effective TNBC treatment.
Keywords: chemodynamic therapy, triple-negative breast cancer, tumor microenvironment, cobalt/manganese-based nano-delivery system, ZIF-67/MnO2/DOX/BSA/SDS